The therapeutic application of this ophthalmic solution is relevant for managing symptoms associated with allergic and irritative eye conditions. The medicine is indicated for use in cases of allergic conjunctivitis.

It may be part of symptomatic management in conditions such as allergic conjunctivitis, including hay-fever and vernal types, and noninfectious irritative conjunctivitis, where supportive symptomatic management is needed. The solution helps address the core symptom cluster of pronounced ocular itching and irritation, alongside the visible manifestations of eye redness (hyperaemia) and conjunctival swelling (chemosis). This contributes to easing the overall symptom load during acute, seasonal, and episodic flare-ups.

“This symptomatic management may assist in maintaining functional stability when symptoms interfere with routine activities.”

This medicine is relevant in clinical settings that involve acute or unstable symptom patterns, supporting patients during episodes of heightened discomfort and temporary functional strain.

Quick Fact: Symptomatic support for Ocular Itching and Redness

Regulatory References

1. Hong Kong Department of Health on Allergic Conjunctivitis treatment

Who can and cannot use Spersallerg?

The population eligibility for using the ophthalmic solution Spersallerg (Antazoline/Tetryzoline) is defined by official regulatory documents, establishing absolute prohibitions and specific caution requirements.

Populations for whom use is Contraindicated

Absolute non-eligibility is documented for the following groups:

• Patients with narrow-angle glaucoma or at risk of angle-closure glaucoma [1.1].
• Patients with known hypersensitivity to any of the active ingredients or excipients [1.2].
• Patients receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing such treatment [1.1].
• Children under 2 years of age are strictly contraindicated due to the risk of systemic absorption and effects [1.2].

Age and Conditional Eligibility

The regulatory profile mandates that Spersallerg is not recommended for use in patients suffering from dry eye syndrome [1.2].

Interactions with other medicines and products

The interaction profile of Spersallerg (Antazoline/Tetryzoline) is defined by the systemic potential of its two active components, requiring strict adherence to documented guidelines regarding co-administration with specific drug classes.

Contraindicated and High-Risk Combinations

The contraindication with MAOIs is absolute and non-negotiable, stemming from the risk of hypertensive crisis caused by the sympathomimetic component, Tetryzoline. The use of other high-risk substances must be assessed for potential additive adverse effects.

Procedural and Population-Specific Constraints

Procedural Constraints: If other topical ophthalmic preparations are administered, an application interval of at least 5 minutes must be observed between the two medications to avoid washout. Spersallerg should generally be applied last.

Population-Specific Notes: The product is not recommended for use in children under 2 years due to a documented greater risk of systemic absorption and effects following accidental ingestion. Use of the sympathomimetic component also requires caution in elderly patients with severe cardiovascular disease.

Spersallerg contains a fixed combination of two active agents, antazoline and tetryzoline, which modulate distinct physiological pathways. Antazoline acts as a competitive H1 receptor antagonist, targeting the signaling cascade initiated by the biogenic amine, histamine. By binding to and blocking peripheral H1 receptors, antazoline inhibits the initial molecular steps of the cascade. This mechanism suppresses the downstream signaling effects of histamine, limiting the pathway activity that leads to increased vascular permeability and capillary vasodilation. Tetryzoline is a sympathomimetic agent that selectively engages alpha-adrenergic receptors. Its alpha-1 adrenergic agonist activity causes a modification of pathway activity by directly stimulating receptors on the vascular smooth muscle. This interaction results in the local vasoconstriction of conjunctival arterioles. The resulting physiological adjustment is a diminished fluid extravasation and decreased hyperemia within the microvasculature of the targeted tissues.

How to Use Spersallerg: Administration Guidelines

Spersallerg is administered exclusively via the Topical Ophthalmic route as a sterile solution, with one drop placed directly into the lower eyelid pocket of the affected eye(s). This method is intended to facilitate localized delivery.

Standard Dosing and Duration

The established standard for administration outlines specific dosing frequencies and a firm duration limit. The usual adult dosage is 1 drop applied 2 to 4 times daily, with frequency dependent on the symptomatic phase. Use should not exceed a maximum duration of 14 consecutive days, defining the protocol as a short-term intervention.

Population-Specific and Procedural Requirements

The standardized protocol includes specific rules for age groups and procedural requirements. For children between 2 and 12 years of age, the regimen is reduced to 1 drop daily or twice daily. The product is not recommended for use in children under 2 years of age.

Key procedural steps must be followed:

• Soft contact lenses must be removed prior to instillation and may be reinserted after at least 15 minutes.
• When using other ophthalmic medications, an interval of at least 5 minutes must be maintained between applications.
• To potentially reduce systemic absorption, closing the eye or using nasolacrimal occlusion for 3 minutes after administration is advised.

These instructions define a standardized protocol, focusing on frequency, a limit on duration, and necessary procedural steps for correct administration.

Research Evidence / Overview of Studies for Spersallerg

Evidence for Use in Allergic Conjunctivitis

Research has focused on understanding the effects of Spersallerg in conditions characterized by fluctuating or episodic manifestations, particularly acute allergic conjunctivitis. Studies for this condition primarily took the form of short-term Randomized Controlled Trials (RCTs) and clinical evaluations. These studies were used in research exploring how symptoms change over time and mainly measured patient-reported outcomes describing perceived discomfort related to ocular itching and irritation. They also monitored visible signs, such as conjunctival redness and swelling (chemosis).

In these research scenarios, findings describe patterns observed in the studies where patients reported changes in outcomes related to physical discomfort. Short-term trials described patterns in patient-reported scores for itching and eye redness during the observed intervals. Research explored short-term symptom changes, and the available data show patterns related to the changes in acute signs and symptoms. This body of evidence contributes to the broader evidence landscape regarding acute symptom changes in this population.

Evidence for Use in Noninfectious Irritative Conjunctivitis

Noninfectious irritative conjunctivitis was evaluated in and was observed in primarily clinical evaluation studies and general clinical use reports, rather than large-scale RCTs. These studies examined subjective outcomes related to physical discomfort, such as general eye irritation and discomfort, and visible signs of redness and swelling.

In these observational settings, studies reported how symptoms evolved in the observed populations, particularly when the medicine was used as a form of supportive symptomatic care. Clinical reports and smaller evaluations described observations of measured changes in irritation and redness during the periods of study. The available research provides insight into short-term changes in these conditions associated with acute or disruptive episodes.

Understanding the Quality and Limitations of the Evidence

The research landscape for Spersallerg is defined by evidence that is categorized as Moderate for acute allergic conjunctivitis and Low for noninfectious irritative conditions. The research is primarily defined by short-term study designs.

Overall, the evidence quality varies across studies. A key limitation is that long-term effects are not fully established, as follow-up durations were limited, typically lasting up to two weeks. Furthermore, the available research does not determine whether an individual will respond similarly to the group patterns described in the studies, as findings describe group patterns, not personal outcomes. The research provides context but not individual predictions.

Key Studies & References

1. [Clinical evaluation of Spersallerg preparation for non-infectious conjunctivitis and infectious conjunctivitis with a hyperergic component] - PubMed
2. Spersallerg Product Information (Regulatory Document)
3. Evidence-based reviews ATC groups S01GA and S01GX - European Directorate for the Quality of Medicines & HealthCare

Common questions about Spersallerg (FAQ)

Q: Does Spersallerg contain any steroids?

According to the official product information, Spersallerg does not contain any steroids as active ingredients. The medicine is classified as an ocular decongestant and antihistamine combination, and its two active components are Antazoline and Tetryzoline.

Q: How quickly should I expect Spersallerg to start working?

Official regulatory documents indicate that the onset of effects, particularly for the reduction of redness (hyperaemia), has been described as occurring rapidly, sometimes within 1 to 5 minutes after application.

Q: How long do the effects of Spersallerg usually last?

Regulatory documents indicate that the effect of the decongestant component, Tetryzoline, is typically described in clinical studies as lasting for a period of 4 to 8 hours. This duration informs the usual administration frequency outlined in prescribing information.

Q: Is Spersallerg available over-the-counter (OTC) in most regions?

In some jurisdictions, Spersallerg is classified as an over-the-counter (OTC) medicine, meaning its regulatory status in those regions permits purchasing without a prescription. However, availability and exact dispensing status are governed by specific national regulations and may differ by country.

Q: Are there warnings about using Spersallerg before driving or operating machinery?

Yes. Patients may experience some visual disturbances, such as blurred vision or drowsiness, immediately after applying the drops. Official prescribing information indicates that if a patient is affected, they must not drive vehicles or operate machinery until the visual disturbances and other symptoms have subsided.

Q: Why is the drug not recommended for people with certain heart conditions?

The active ingredient Tetryzoline is a sympathomimetic agent, meaning it affects the nervous system pathways that control vascular smooth muscle. Systemic absorption of this component can lead to cardiovascular effects, including tachycardia (rapid heart rate) and hypertension (raised blood pressure). For this reason, caution is advised for patients with severe cardiovascular disease or uncontrolled high blood pressure.

Q: Why does Spersallerg sometimes cause a stinging or burning feeling when first used?

The most common adverse event reported in regulatory documents is a transient (temporary) irritation or burning sensation immediately after putting the drops in. Although the specific cause is not detailed in the official texts, this is a known and expected effect upon initial application.

Q: Does Spersallerg interact with blood pressure medicine?

Official information indicates that Spersallerg is contraindicated (must not be used) with Monoamine Oxidase Inhibitors (MAOIs), including for up to two weeks after stopping them, due to the risk of severe blood pressure spikes. Additionally, caution is advised when using it alongside medications like tricyclic antidepressants, which can affect blood pressure.

Q: Is it common to have blurry vision for a short time after using Spersallerg?

Official documents report that blurred vision is a possible adverse effect, especially if the medicine is systemically absorbed. This effect is described as transient (short-lived), and regulatory documents indicate that if vision is affected, operating machinery or driving must be avoided until vision is fully clear.

Q: Does Spersallerg contain a preservative, and if so, what kind?

Yes, Spersallerg contains the preservative benzalkonium chloride. Regulatory documents highlight this because the component can be absorbed by soft contact lenses, necessitating their removal before using the drops.

Q: Is Spersallerg known to interact with anti-depressant medication?

Yes. The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). Furthermore, official labels indicate that the Tetryzoline component may cause an increase in blood pressure when used with tricyclic antidepressants.

Q: Is Spersallerg designed to treat the cause of the allergy or just the symptoms?

Spersallerg is indicated for the symptomatic relief of allergic eye disease. Its components are designed to block the immediate effects of the allergic response (Antazoline) and reduce visible signs like redness and swelling (Tetryzoline), rather than curing the underlying allergic condition.

Q: Is the eye drop preservative safe for long-term eye health?

The preservative benzalkonium chloride has been associated in some regulatory reports with potential eye irritation and dry eye, particularly with prolonged use. For this reason, official guidance for Spersallerg indicates that use should not exceed 14 consecutive days and is not recommended for extended use.

How to Store and Dispose of Spersallerg: Official Requirements

Storage Conditions and Stability

Spersallerg Ophthalmic Solution must be stored in a cool place at a temperature at or below 25°C. The bottle must be kept in its original container, tightly closed, and it is explicitly required that the solution must not be frozen. To ensure product stability and sterility, the medicine must not be used for longer than 30 days after the bottle is first opened. It should never be used past the expiry date (EXP) printed on the packaging.

Handling and Disposal

The medicine is required to be kept out of the reach and sight of children. Expired or unused Spersallerg must not be disposed of by pouring it down the drain or throwing it in household waste. Unused or unwanted product must be returned to a pharmacist or an appropriate local waste disposal company to ensure proper management of pharmaceutical waste.